StreetInsider.com News Articles

Rhelion unit signs psilocybin supply deal with Dutch research center

Thu, 17 Sep 2026 07:54:11 -0400

Rhelion Life Sciences Corp. (CSE: RHEL, FSE: 4YX0, OTCQB: TRUFF) announced that its wholly owned subsidiary, Filament Health Corp., has entered into a supply and licensing agreement with the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands.

Under the agreement, Filament will supply its botanical psilocybin drug candidate PEX010 in 1 mg and 5 mg doses, along with matching placebo capsules, for a CHDR-sponsored study examining low and medium dose psilocybin. The study is being conducted in collaboration with the PRSM Lab at Leiden University and has received funding from Norrsken Mind.

Filament will also provide regulatory support for the

Rhelion unit signs psilocybin supply deal with Dutch research center

Thu, 17 Sep 2026 07:54:11 -0400

Filament will also provide regulatory support for the

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010 in a Study of Low and Medium Dose Psilocybin

Thu, 17 Sep 2026 07:52:00 -0400

Filament will supply PEX010 1 mg and 5 mg capsules, with matching placebo, for a study of low and medium dose psilocybin sponsored by the Centre for Human Drug Research in Leiden, the Netherlands.

Toronto, Ontario--(Newsfile Corp. - September 17, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly owned subsidiary Filament Health Corp. ("Filament"), the Company develops, manufactures and supplies PEX010, its patented, standardized, GMP manufactured botanical psilocybin drug candidate, to clinical research and compassionate access programs at

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010 in a Study of Low and Medium Dose Psilocybin

Thu, 17 Sep 2026 07:52:00 -0400

Filament will supply PEX010 1 mg and 5 mg capsules, with matching placebo, for a study of low and medium dose psilocybin sponsored by the Centre for Human Drug Research in Leiden, the Netherlands.

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010 in a Study of Low and Medium Dose Psilocybin

Thu, 17 Sep 2026 07:52:00 -0400

Filament will supply PEX010 1 mg and 5 mg capsules, with matching placebo, for a study of low and medium dose psilocybin sponsored by the Centre for Human Drug Research in Leiden, the Netherlands.

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010 in a Study of Low and Medium Dose Psilocybin

Thu, 17 Sep 2026 07:52:00 -0400

Filament will supply PEX010 1 mg and 5 mg capsules, with matching placebo, for a study of low and medium dose psilocybin sponsored by the Centre for Human Drug Research in Leiden, the Netherlands.

Rhelion unit signs USC supply deal for psilocybin drug candidate

Tue, 15 Sep 2026 08:00:16 -0400

Rhelion Life Sciences Corp. (CSE: RHEL, FSE: 4YX0, OTCQB: TRUFF) announced that its wholly owned subsidiary, Filament Health Corp., has entered into a supply and licensing agreement with the University of Southern California's Keck School of Medicine for its botanical psilocybin drug candidate, PEX010.

Under the agreement, PEX010 will be supplied as the investigational drug product for a study examining whether structured mindfulness meditation training can augment psilocybin-assisted therapy, including in a clinical depression cohort. Filament is not the sponsor of the trial and is not responsible for its conduct.

PEX010 is produced using Filament's proprietary extraction, purification, and stabilization methods, which

Rhelion unit signs USC supply deal for psilocybin drug candidate

Tue, 15 Sep 2026 08:00:16 -0400

Rhelion Life Sciences Corp. (CSE: RHEL, FSE: 4YX0, OTCQB: TRUFF) announced that its wholly owned subsidiary, Filament Health Corp., has entered into a supply and licensing agreement with the University of Southern California's Keck School of Medicine for its botanical psilocybin drug candidate, PEX010.

PEX010 is produced using Filament's proprietary extraction, purification, and stabilization methods, which

Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the University of Southern California for PEX010 in a Trial for Psilocybin-Assisted Mindfulness

Tue, 15 Sep 2026 07:59:00 -0400

Toronto, Ontario--(Newsfile Corp. - September 15, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to announce that its wholly owned subsidiary, Filament Health Corp. ("Filament"), has entered into a supply and licensing agreement with the University of Southern California, on behalf of its Keck School of Medicine of USC, for the supply of PEX010, Filament's patented, standardized, GMP manufactured botanical psilocybin drug candidate.

PEX010 will be supplied for Psilocybin Assisted Mindfulness Therapy.

Filament supplies PEX010 as the investigational drug product.

Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the University of Southern California for PEX010 in a Trial for Psilocybin-Assisted Mindfulness

Tue, 15 Sep 2026 07:59:00 -0400

PEX010 will be supplied for Psilocybin Assisted Mindfulness Therapy.

Filament supplies PEX010 as the investigational drug product.

Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the University of Southern California for PEX010 in a Trial for Psilocybin-Assisted Mindfulness

Tue, 15 Sep 2026 07:59:00 -0400

PEX010 will be supplied for Psilocybin Assisted Mindfulness Therapy.

Filament supplies PEX010 as the investigational drug product.

Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the University of Southern California for PEX010 in a Trial for Psilocybin-Assisted Mindfulness

Tue, 15 Sep 2026 07:59:00 -0400

PEX010 will be supplied for Psilocybin Assisted Mindfulness Therapy.

Filament supplies PEX010 as the investigational drug product.

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Deliver Oral Comments at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs

Mon, 14 Sep 2026 07:53:00 -0400

Sarit Hashkes, President of Filament Health Corp., will provide oral remarks at the United States Food and Drug Administration public hearing "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs", being held later today, September 14, 2026

Toronto, Ontario--(Newsfile Corp. - September 14, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to announce that Sarit Hashkes, President of its wholly owned subsidiary Filament Health Corp. ("Filament"), will deliver oral comments at the United States Food and Drug Administration ("FDA")

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Deliver Oral Comments at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs

Mon, 14 Sep 2026 07:53:00 -0400

Sarit Hashkes, President of Filament Health Corp., will provide oral remarks at the United States Food and Drug Administration public hearing "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs", being held later today, September 14, 2026

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Deliver Oral Comments at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs

Mon, 14 Sep 2026 07:53:00 -0400

Sarit Hashkes, President of Filament Health Corp., will provide oral remarks at the United States Food and Drug Administration public hearing "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs", being held later today, September 14, 2026

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Deliver Oral Comments at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs

Mon, 14 Sep 2026 07:53:00 -0400

Sarit Hashkes, President of Filament Health Corp., will provide oral remarks at the United States Food and Drug Administration public hearing "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs", being held later today, September 14, 2026

Rhelion Life Sciences Announces Filament Health is Planning a Stability Program for IBEX011, Its Naturally Derived Ibogaine Drug Candidate

Thu, 10 Sep 2026 07:55:00 -0400

Filament Health has begun planning a stability program for IBEX011, its naturally derived botanical ibogaine drug candidate, in response to growing demand for GMP quality, standardized ibogaine for clinical research.

Toronto, Ontario--(Newsfile Corp. - September 10, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly owned subsidiary Filament Health Corp. ("Filament"), the Company develops, manufactures and supplies PEX010, its patented, standardized, GMP manufactured botanical psilocybin drug candidate, to clinical research and compassionate access programs at leading institutions worldwide.

The Company

Rhelion Life Sciences Announces Filament Health is Planning a Stability Program for IBEX011, Its Naturally Derived Ibogaine Drug Candidate

Thu, 10 Sep 2026 07:55:00 -0400

Filament Health has begun planning a stability program for IBEX011, its naturally derived botanical ibogaine drug candidate, in response to growing demand for GMP quality, standardized ibogaine for clinical research.

The Company

Rhelion Life Sciences Announces Filament Health is Planning a Stability Program for IBEX011, Its Naturally Derived Ibogaine Drug Candidate

Thu, 10 Sep 2026 07:55:00 -0400

Filament Health has begun planning a stability program for IBEX011, its naturally derived botanical ibogaine drug candidate, in response to growing demand for GMP quality, standardized ibogaine for clinical research.

The Company

Rhelion Life Sciences Announces Filament Health is Planning a Stability Program for IBEX011, Its Naturally Derived Ibogaine Drug Candidate

Thu, 10 Sep 2026 07:55:00 -0400

Filament Health has begun planning a stability program for IBEX011, its naturally derived botanical ibogaine drug candidate, in response to growing demand for GMP quality, standardized ibogaine for clinical research.

The Company

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 to Australia for University of Melbourne Trial of Psilocybin-Assisted Physiotherapy in Functional Neurologic

Tue, 08 Sep 2026 07:52:00 -0400

Filament Health's patented, naturally derived psilocybin drug candidate PEX010 has been shipped to Austin Health in Melbourne for PSI-PHY, an investigator initiated pilot trial of psilocybin-assisted physiotherapy in refractory motor functional neurological disorder, sponsored by The University of Melbourne and funded by the Australian Government's Medical Research Future Fund
The study is the first trial of PEX010 in a movement disorder and, to the Company's knowledge, the first anywhere to combine a psychedelic with physiotherapy

Toronto, Ontario--(Newsfile Corp. - September 8, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 to Australia for University of Melbourne Trial of Psilocybin-Assisted Physiotherapy in Functional Neurologic

Tue, 08 Sep 2026 07:52:00 -0400

Filament Health's patented, naturally derived psilocybin drug candidate PEX010 has been shipped to Austin Health in Melbourne for PSI-PHY, an investigator initiated pilot trial of psilocybin-assisted physiotherapy in refractory motor functional neurological disorder, sponsored by The University of Melbourne and funded by the Australian Government's Medical Research Future Fund
The study is the first trial of PEX010 in a movement disorder and, to the Company's knowledge, the first anywhere to combine a psychedelic with physiotherapy

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 to Australia for University of Melbourne Trial of Psilocybin-Assisted Physiotherapy in Functional Neurologic

Tue, 08 Sep 2026 07:52:00 -0400

Filament Health's patented, naturally derived psilocybin drug candidate PEX010 has been shipped to Austin Health in Melbourne for PSI-PHY, an investigator initiated pilot trial of psilocybin-assisted physiotherapy in refractory motor functional neurological disorder, sponsored by The University of Melbourne and funded by the Australian Government's Medical Research Future Fund
The study is the first trial of PEX010 in a movement disorder and, to the Company's knowledge, the first anywhere to combine a psychedelic with physiotherapy

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 to Australia for University of Melbourne Trial of Psilocybin-Assisted Physiotherapy in Functional Neurologic

Tue, 08 Sep 2026 07:52:00 -0400

Filament Health's patented, naturally derived psilocybin drug candidate PEX010 has been shipped to Austin Health in Melbourne for PSI-PHY, an investigator initiated pilot trial of psilocybin-assisted physiotherapy in refractory motor functional neurological disorder, sponsored by The University of Melbourne and funded by the Australian Government's Medical Research Future Fund
The study is the first trial of PEX010 in a movement disorder and, to the Company's knowledge, the first anywhere to combine a psychedelic with physiotherapy

Rhelion Life Sciences Confirms Further Delivery of Filament Health's PEX010 to Germany's First Psilocybin Compassionate Use Program

Thu, 03 Sep 2026 07:39:00 -0400

Filament Health has completed a further international delivery of its patented, naturally derived psilocybin drug candidate PEX010 to Germany, supporting the first compassionate use program for psilocybin in the European Union
The Company believes the continued delivery demonstrates Filament's ability to manufacture, release and supply pharmaceutical-grade botanical psilocybin across international regulatory jurisdictions as new legal access pathways emerge
Rhelion intends to leverage Filament's existing GMP manufacturing infrastructure, regulatory experience, intellectual property and international supply capabilities to pursue future commercial supply opportunities as regulated psilocybin markets and patient-access programs develop globally

Toronto, Ontario--(Newsfile Corp. - September 3, 2026) - Rhelion Life Sciences Corp. (CSE: